Thymosin Alpha-1 vs Epitalon Side-Effect Profile Head-to-Head

HealthRX.com

Thymosin alpha-1 has trial harm data; epitalon has none

Print or save as PDF

Key numbers

  • 1,349 adultsAdults with chronic hepatitis B pooled across 10 randomized trials in the 2026 Cochrane review of thymosin alpha-1Source: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 1.6 mgItalian Zadaxin label dose of thymosin alpha-1 given twice weekly, a product sold outside the USSource: fda.gov, as cited Nov 7, 2026
  • 0.5 mg/dayEpitalon dose used in human studies by sublingual spray, not a recommended doseSource: fda.gov, as cited Nov 7, 2026
  • 17 million dosesZadaxin doses given after marketing, reported by manufacturer-linked authors with 'infrequent and mild' adverse experiencesSource: fda.gov, as cited Nov 7, 2026
  • FDA approval / Neither is FDA-approved: thymosin alpha-1 has no US application [2], and epitalon is not an approved drug or a component of one; FDA found no EMA authorization and no approved product in the European countries it checked, the UK, Canada or Australia [3]
  • Thymosin alpha-1 trial harms / Fewer serious adverse events than comparators in a 2026 Cochrane review (RR 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people) [1]
  • Thymosin alpha-1 reports / Zero in FDA's adverse-event database as of April 22, 2024 [2]
  • Epitalon safety data / No clinical study has assessed it [3]
  • Epitalon reports / Zero retrieved from FDA's adverse-event database through December 8, 2025 [3]
  • Shared regulatory concern / FDA posts immunogenicity and impurity concerns for both as compounded peptides (for thymosin alpha-1, for certain routes of administration) [4]
  • Approved dose / None in the US for either; Italy's Zadaxin label uses 1.6 mg twice weekly [2]
  • Epitalon doses used in studies / About 0.5 mg/day by sublingual spray for 20 days; injection beside the eye for retinitis pigmentosa [3]

Which peptide has the better-documented side-effect profile?

Thymosin alpha-1. Its harms have been counted in randomized trials: a 2026 Cochrane review pooled 10 randomized trials with 1,349 adults with chronic hepatitis B, published between 1991 and 2018, run in Bangladesh, China, Italy, Korea, Singapore and Taiwan [1]. For epitalon, FDA found only three human studies, two sublingual and one eye injection [3].

Thymosin alpha-1: what the trials show about harm

In the Cochrane review, thymosin alpha-1 given alone or with interferon, lamivudine, entecavir or tenofovir was compared with placebo, no treatment or the same co-treatment. It may have caused fewer serious adverse events than the comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious adverse events (RR 0.47, 95% CI 0.27 to 0.83; very low-certainty evidence) [1]. The same review found possible lower all-cause mortality (RR 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people) at very low certainty, little to no effect on quality of life or liver histology, and reviewers who said they are not sure the drug helps [1].

Smaller trials add little on harm. A double-blind trial of 98 adults given lymphoblastoid interferon plus thymosin alpha-1 (n=48) or plus placebo (n=50) had an efficacy primary endpoint: HBeAg loss at 72 weeks was 45.8% versus 28.0% (difference 17.8%, 95% CI -1.2 to 35.3, P=0.067), not statistically significant [5]. A 1991 placebo-controlled pilot in 12 people reported no significant side effects in either group [6].

Where the 'infrequent and mild' reputation comes from

Two places, both limited. Authors tied to the manufacturer report more than 4,400 people enrolled in trials and more than 17 million doses of Zadaxin given after marketing, with adverse experiences described as 'infrequent and mild' — company-linked data [2]. Separately, FDA's search of its adverse-event database on April 22, 2024 found zero reports for thymosin alpha-1 [2].

Epitalon: what is known about harm

Very little, and none of it clinical. FDA's July 2026 evaluation found only three human studies — two sublingual studies in night-shift workers and one eye-injection study in retinitis pigmentosa — and no clinical study assessing safety, plus no pharmacokinetic data at all [3]. Its adverse-event database search through December 8, 2025 and its food and supplement complaint search through December 5, 2025 retrieved no epitalon reports [3]. One Russian-language report said only 'no side effects', without a dose, route or number of people [3].

The one human study with usable detail: a placebo-controlled study of 75 healthy women aged 40 to 50, mostly night-shift workers, of whom 40 with low melatonin output were split into two groups of 20. They received a sublingual spray delivering about 0.5 mg/day or placebo for 20 days. Urinary 6-sulfatoxymelatonin rose about 1.7-fold on epitalon and did not change on placebo, and 83% versus 25% were described as improved in mood and physical condition — but no sleep outcomes were measured and blinding was not specified [3].

Older work: a 2002 controlled clinical study in degenerative retinal lesions reported a 'positive clinical effect in 90% of the cases', with epitalon injected beside the eye. The abstract gives no sample sizes, design details or numbers, and the result has not been replicated [7].

Does epitalon carry a cancer concern?

FDA raised one on mechanistic grounds. In cultured human fetal fibroblasts that lack telomerase, epitalon induced telomerase activity and telomere elongation [8] — a cell-culture result, not a human one. FDA warned that because epitalon activates telomerase and lengthens telomeres, and longer telomeres are generally linked to higher cancer risk, it has a mechanistic potential to be carcinogenic, and it judged the mouse studies of cancer and chromosome damage too limited — one fixed dose, female mice only, short exposure — to show safety [3]. A 2026 narrative review concluded that oncologic, immunogenicity, product-quality and regulatory uncertainties remain unresolved [9].

Immunogenicity and impurity: the concern both peptides share

For thymosin alpha-1, FDA lists a 'significant risk for immunogenicity for certain routes of administration', peptide-impurity and characterization problems, and safety information 'inadequate for the agency to sufficiently understand the extent of any safety issues' [4]. For epitalon, FDA says it 'has not identified safety-related information regarding epitalon for the proposed route of administration' and notes that injectable peptides may pose immunogenicity risk from aggregation and impurities [4]; its 2026 evaluation specifically raised an immunogenicity concern for subcutaneous injection [3].

Both substances sit in the 'nominated but withdrawn' table on FDA's page about bulk substances that may raise significant safety risks when compounded — substances previously in category 2 whose nominators withdrew them. Removal from that category was not a finding that they are safe [4].

What the labels say

There is no US label for either peptide. Italy's Zadaxin label covers 1.6 mg powder given subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first influenza vaccination, repeated from week 8 to week 12 at the second vaccination. That label says not for children, contraindicated in pregnancy and breastfeeding, caution in people with allergies or autoimmune disease, and caution with other immune-modulating drugs [2]. Zadaxin is a finished injection sold outside the US and is not interchangeable with bulk thymosin alpha-1 powder [2]. Nothing comparable exists for epitalon, and it has no approved dose [3].

Dosing that appears in studies, not recommended doses

Thymosin alpha-1 has no US-approved dose [2]. The Italian Zadaxin schedule above applies to a product sold outside the US [2]. For epitalon, websites FDA examined suggest 5 mg to 10 mg per day by subcutaneous injection or orally in cycles — marketing, not evidence. The human studies FDA found used a sublingual spray delivering about 0.5 mg/day for 20 days, and a parabulbar injection for retinitis pigmentosa [3].

Regulatory status: does it change the risk picture?

Neither peptide is FDA-approved. Thymosin alpha-1 holds four US orphan drug designations, which are a separate process from approval [2]; in December 2024 FDA's compounding advisory committee voted 4 yes and 17 no on adding it to the bulks list, with members who voted no citing no compelling evidence of clinical effectiveness and safety [10]. Epitalon is not an approved drug or a component of one and has no pharmacopeial monograph; FDA found no EMA authorization and no approved product in the European countries it checked, the UK, Canada or Australia; its 2010 orphan designation for retinitis pigmentosa was withdrawn in January 2016 [3]. The same committee voted in July 2026 in favor of adding epitalon to the bulks list, against FDA staff's recommendation — advice only, not binding [11][12]. HHS's October 2026 draft enforcement-discretion policy names epitalon and not thymosin alpha-1, and is neither an approval nor a listing [12][13]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [12].

Bottom line

Thymosin alpha-1 has trial harm data: a Cochrane harm analysis and an Italian Zadaxin label that names its cautions [1][2]. For epitalon, FDA found no clinical safety data and raised a potential cancer concern based on its mechanism [3]. The evidence on the two peptides comes from separate studies, not a head-to-head safety comparison.

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to the article, which peptide has no clinical safety data at all?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Questions worth asking

Choose the questions you want to keep

Which peptide has more side-effect data?
Thymosin alpha-1. A 2026 Cochrane review pooled 10 randomized trials with 1,349 adults with chronic hepatitis B and reported harm outcomes [1], while epitalon's human evidence is limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa [9].
What side effects have been reported with epitalon?
FDA's adverse-event database search through December 8, 2025 and its food and supplement complaint system search through December 5, 2025 retrieved no epitalon reports, and one Russian-language report said only 'no side effects', without a dose, route or number of people [3].
Is thymosin alpha-1 well tolerated in trials?
In the Cochrane review of hepatitis B trials it may have caused fewer serious (RR 0.72) and fewer non-serious (RR 0.47) adverse events than comparison treatments, at low and very low certainty [1]. Manufacturer-linked authors describe adverse experiences as infrequent and mild across more than 17 million post-marketing doses [2].
Can epitalon cause cancer?
It has not been shown to, and it has not been shown not to. FDA warned of a mechanistic potential to be carcinogenic because epitalon activates telomerase in cultured cells [8] and longer telomeres are generally linked to higher cancer risk, and it judged the mouse cancer studies too limited to show safety [3].
Is either peptide FDA-approved?
No. Thymosin alpha-1 holds four US orphan drug designations, which are not approvals [2], and epitalon is not an approved drug or a component of one in the US; FDA found no EMA authorization and no approved product in the European countries it checked, the UK, Canada or Australia [3].
Does compounding change the risk?
Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [12]. FDA also posts immunogenicity and impurity concerns for both peptides [4].
Show all 13 referencesHide references
  1. Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026.
  2. U.S. Food and Drug Administration.
  3. U.S. Food and Drug Administration.
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  5. Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther. 2006;11(2):245-53.
  6. Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology. 1991;14(3):409-15.
  7. Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365-8.
  8. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-2.
  9. Jain A, Gallacher DM, Issa MA, Deer TR, Yong RJ, Diwan S, et al. Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence. Int J Mol Sci. 2026.
  10. U.S. Food and Drug Administration.
  11. U.S. Food and Drug Administration.
  12. Official web page.
  13. Official web page.
Evidence overview for Thymosin Alpha-1 vs Epitalon Side-Effect Profile Head-to-Head